MedPath

Amifostine

Generic Name
Amifostine
Brand Names
Ethyol
Drug Type
Small Molecule
Chemical Formula
C5H15N2O3PS
CAS Number
20537-88-6
Unique Ingredient Identifier
ILA426L95O
Background

A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.

Indication

For reduction in the cumulative renal toxicity in patients with ovarian cancer (using cisplatin) and moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer.

Associated Conditions
Dry Mouth, Nephrotoxicity, Prophylaxis of Radiation proctitis
Clinical Trials
Related News

High Dose Chemotherapy With Amifostine and Autologous Stem Cell Transplantation for High Risk Relapsed Pediatric Solid Tumors and Brain Tumors

Phase 2
Terminated
Conditions
Solid Tumors
Brain Tumors
Interventions
First Posted Date
2021-12-22
Last Posted Date
2022-01-25
Lead Sponsor
Children's Hospital Medical Center, Cincinnati
Target Recruit Count
2
Registration Number
NCT05167370
Locations
🇺🇸

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

Radiation-protection Effect of Amifostine in Locally Advanced Rectal Cancer

Phase 2
Conditions
Locally Advanced Rectal Cancer
Interventions
Radiation: Radiation
First Posted Date
2018-10-11
Last Posted Date
2019-01-23
Lead Sponsor
Fudan University
Target Recruit Count
160
Registration Number
NCT03702985
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Study of Cytoreductive Surgery and Hyperthermic Intrathoracic Pleural Chemotherapy (HITC) With Escalating Doses for Children and Adolescents With Unilateral Pleural Malignancy

Phase 1
Completed
Conditions
Lung Cancer
Interventions
First Posted Date
2013-11-29
Last Posted Date
2023-09-14
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
7
Registration Number
NCT01998529
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

A Phase II Clinical Trial on Comparison of Effectiveness and Safeness of Different Amifostine Regimens

Phase 2
Conditions
Bone Marrow Diseases
Nasopharyngeal Neoplasms
Salivary Gland Diseases
Mucositis
Interventions
First Posted Date
2013-01-07
Last Posted Date
2017-07-13
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
360
Registration Number
NCT01762514
Locations
🇨🇳

The Main Guangzhou Hospital of the Guangzhou Military Region, Guangzhou, Guangdong, China

🇨🇳

The Affiliated Cancer Hospital Of Guangzhou Medical Collage, Guangzhou, Guangdong, China

🇨🇳

The First Affiliated Hospital Of Guangzhou Medical Collage, Guangzhou, Guangdong, China

and more 4 locations

A Phase II Study of Amifostine for the Prevention of Acute Radiation-Induced Rectal Toxicity

Phase 2
Conditions
Rectal Cancer
Interventions
First Posted Date
2012-04-26
Last Posted Date
2013-08-15
Lead Sponsor
Chinese Academy of Medical Sciences
Target Recruit Count
40
Registration Number
NCT01586117
Locations
🇨🇳

Radiation Oncology Depratment, Cancer Hospital, CAMS, Beijing, Beijing, China

A Study of Amifostine for Prevention of Facial Numbness in Radiosurgery Treatment of Trigeminal Neuralgia

Phase 3
Terminated
Conditions
Trigeminal Neuralgia
Interventions
Procedure: CyberKnife stereotactic radiosurgery
First Posted Date
2011-06-02
Last Posted Date
2017-04-04
Lead Sponsor
Stanford University
Target Recruit Count
17
Registration Number
NCT01364259
Locations
🇺🇸

Stanford University School of Medicine, Stanford, California, United States

Prospective Study of Head and Neck Cancer Radiation Treatment With or Without Amifostine

Phase 4
Withdrawn
Conditions
Stomatitis
Oral Mucositis
Interventions
First Posted Date
2011-02-02
Last Posted Date
2021-11-17
Lead Sponsor
Sun Pharmaceutical Industries Limited
Registration Number
NCT01288625

A Study of Amifostine (Ethyol) in Patients With Colorectal Cancer

Phase 2
Terminated
Conditions
Colorectal Cancer
Interventions
First Posted Date
2008-01-25
Last Posted Date
2023-08-01
Lead Sponsor
University of Cincinnati
Target Recruit Count
4
Registration Number
NCT00601198
Locations
🇺🇸

University of Cincinnati, Cincinnati, Ohio, United States

Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma

Phase 1
Completed
Conditions
Malignant Pleural Mesothelioma
Interventions
Procedure: Extrapleural pneumonectomy (EPP)
Procedure: Pleurectomy/Decortication
First Posted Date
2007-12-11
Last Posted Date
2017-01-23
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
141
Registration Number
NCT00571298
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia

Phase 2
Terminated
Conditions
Dysphagia
Head and Neck Cancer
Mucositis
Xerostomia
Interventions
Behavioral: exercise intervention
Procedure: therapeutic dietary intervention
First Posted Date
2007-07-19
Last Posted Date
2017-06-20
Lead Sponsor
Vanderbilt-Ingram Cancer Center
Target Recruit Count
41
Registration Number
NCT00503776
Locations
🇺🇸

Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy